UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): March 2, 2020

 

Z:2020 OPERATIONS2020 EDGAR03 MARCHENDONOVO THERAPEUTICS, INC03-01-2020FORM 8-KDRAFTPRODUCTION  

 

ENDONOVO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   000-55453   45-2552528
(State or other jurisdiction
of incorporation) 		  (Commission
File Number) 		  (IRS Employer
Identification No.)

 

6320 Canoga Avenue, 15th Floor

Woodland Hills, CA 91367

(Address of principal executive office)(Zip Code)

 

Registrant’s telephone number, including area code: (800) 489-4774

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
 Common Stock, par value $0.0001 per share  

ENDV

 

OTCQB

 

 

 

     
 

 

Item 8.01 Other Events.

 

On March 2, 2020, the Registrant’s released a presentation on SofPulse® the company’s flagship Electrocuetical® device. The presentation will be utilized to expand the current US market rollout for SofPulse® and will be presented at various upcoming investment and medical conferences, seminars, presentations and institutional investor meetings.

 

Item 9.01 Financial Statements and Exhibits.

 

(a) Financial Statements

 

None

 

(b) Exhibits

 

99.1 Presentation regarding SofPulse®.

 

     
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: March 2, 2020

 

  ENDONOVO THERAPEUTICS, INC.
     
  By: /s/ Alan Collier
    Alan Collier
    Chief Executive Officer

 

     

 

Endonovo Therapeutics (PK) (USOTC:ENDV)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024 Plus de graphiques de la Bourse Endonovo Therapeutics (PK)
Endonovo Therapeutics (PK) (USOTC:ENDV)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024 Plus de graphiques de la Bourse Endonovo Therapeutics (PK)